Related Experiment Video
Updated: Jul 8, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Human papillomavirus vaccines in development: if they're successful in clinical trials, how will they be implemented?
1Merck Vaccine Division, West Point, PA 19486, USA.
Introduction:
There are some 30-40 genotypes of human papillomavirus (HPV) that cause anogenital lesions in humans, primarily cervical, vaginal, and vulvar dysplasias and cancer in women, anal dysplasias in some men, and genital warts in both sexes.
Methods:
Both GlaxoSmithKline and Merck companies are developing vaccines for the prevention of HPV infection.
Results:
Both vaccines stimulate an antibody response against HPV types 16 and 18; the Merck vaccine also include HPV types 6 and 11.
Conclusions:
This report focuses on progress with both prophylactic vaccines and introduces strategies for global immunization.
Related Concept Videos
Vaccinations
Clinical Trials: Overview
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccine Production
Vaccines
Poliomyelitis

